Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 75/100

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monday, January 6, 2025 2 min read
Key Takeaway: Ardelyx, Inc. has announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. This event will showcase Ardelyx's ongoing commitment to develop first-in-class medications that address unmet medical needs. The conference aims to provide insights into the company's advancements and future endeavors. Ardelyx currently offers two commercial products approved in the U.S., both utilizing the active ingredient tenapanor.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is participating in a significant industry conference.
  • The company is presenting innovative solutions for unmet medical needs.
  • They have two approved commercial products in the U.S.

Full Press Release Details

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When will Ardelyx present at the J.P. Morgan Healthcare Conference?

Ardelyx will present on January 15, 2025, at 4:30pm PT.

How can I access the Ardelyx presentation online?

View the live webcast on Ardelyx's Events and Presentations page.

What products does Ardelyx have approved in the U.S.?

Ardelyx has IBSRELA® and XPHOZAH® approved for marketing in the U.S.

Who commercializes tenapanor in Japan?

Kyowa Kirin is responsible for commercializing PHOZEVEL® in Japan.

Is there a replay of the Ardelyx presentation available?

Yes, a replay will be accessible on their website for 30 days after the event.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx tenapanor J.P. Morgan Healthcare Conference biopharmaceuticals IBSRELA
Last updated: Jan 6, 2025